AR080019A1 - 5- alquinil -pirimidinas - Google Patents

5- alquinil -pirimidinas

Info

Publication number
AR080019A1
AR080019A1 ARP110100240A ARP110100240A AR080019A1 AR 080019 A1 AR080019 A1 AR 080019A1 AR P110100240 A ARP110100240 A AR P110100240A AR P110100240 A ARP110100240 A AR P110100240A AR 080019 A1 AR080019 A1 AR 080019A1
Authority
AR
Argentina
Prior art keywords
membered
nrg41rg42
nre5re55
nrc5rc55
independently
Prior art date
Application number
ARP110100240A
Other languages
English (en)
Inventor
Tobias Wunberg
Dirk Kessler
Der Veen Lars Van
Siegfried Schneider
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42140100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080019(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR080019A1 publication Critical patent/AR080019A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Son adecuados para el tratamiento de enfermedades caracterizadas por una proliferacion celular excesiva o anormal, y al uso de los mismos para preparar un medicamento que tiene las propiedades mencionadas anteriormente. Reivindicacion 1: Compuestos caracterizados por la formula general (1), en la que R3 representa un grupo seleccionado entre cicloalquilo C3-8, heterocicloalquilo de 3-8 miembros, arilo C6-10 y heteroarilo de 5-12 miembros, opcionalmente sustituido con uno o más R4 iguales o diferentes; y R1 representa un grupo seleccionado entre cicloalquilo C3-8, heterocicloalquilo de 3-13 miembros y heteroalquilo de 2-6 miembros, opcionalmente sustituido con uno o más R5 iguales o diferentes y R2 representa un grupo seleccionado entre hidrogeno, alquilo C1-4, heteroalquilo de 3-8 miembros, haloalquilo C1-4, cicloalquilo C3-8, heterocicloalquilo de 3-8 miembros, -ORv, -NRvRv, -SRv, -CF3, -CHF2, -CH2F, -CN, -NC y -NO2, y cada R4 representa un grupo seleccionado entre Ra y Rb; y cada Ra representa independientemente hidrogeno o un grupo seleccionado entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, donde Ra está opcionalmente sustituido con uno o más Rb y/o Rc4 iguales o diferentes; cada Rb representa un grupo adecuado y se selecciona independientemente entre otro de -ORc41, haloalquiloxi C1-3, -OCF3, -OCHF2, -SRc41, -NRc41Rc42, -ONRc41Rc42, -N(ORc41)Rc42, -N(Rg)NRc41Rc42, halogeno, -CF3, -CHF2, -CH2F, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, y cada R4, Rc41 y Rc42, independientemente entre sí, representa hidrogeno o un grupo seleccionado entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, donde Rc41 y Rc42 están opcionalmente sustituidos independientemente con uno o más Rd y/o Re4 iguales o diferentes, y donde Rc41 y Rc42 tomados juntos pueden formar un resto heterocicloalquilo de 3-8 miembros a través de un átomo compartido de C, N, O o S, y cada Rd representa un grupo adecuado y se selecciona independientemente entre otro de -ORe41, haloalquiloxi C1-3, -OCF3, -OCHF2, -SRe41, -NRe41Re42, -ONRe41Re42, -N(R9)NRe1Re42, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3 y cada Re4, Re41 y Re42, independientemente entre sí, representa hidrogeno o un grupo seleccionado entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, donde Re41 y Re42 están opcionalmente sustituidos independientemente con uno o más Rf y/o Rg4 iguales o diferentes, y donde Re41 y/o Re42 tomados juntos pueden formar un resto heterocicloalquilo de 3-8 miembros a través de un átomo compartido de C, N, O o S y cada Rf representa un grupo adecuado y, en cada caso, se selecciona independientemente entre otro de =O, -ORg41, haloalquiloxi C1-3, -OCF3, -OCHF2, =S, -SRg41, =NRg41, =NORg41, =NNRg41Rg42, =NN(Rh)C(O)NRg41Rg42, -NRg41Rg42, -ONRg41Rg42, -N(Rh)NRg41Rg42, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)Rg41, -S(O)ORg41, -S(O)2Rg41, -S(O)2ORg41, -S(O)NRg41Rg42, -S(O)2NRg41Rg42, -OS(O)Rg41, -OS(O)2Rg41, -OS(O)2ORg41, -OS(O)NRg41Rg42, -OS(O)2NRg41Rg42, -C(O)Rg41, -C(O)ORg41, -C(O)SRg41, -C(O)NRg41Rg42, -C(O)N(Rh)NRg41Rg42, -C(O)N(Rh)ORg41, -C(NRh)NRg41Rg42, -C(NOH)Rg41, -C(NOH)NRg41Rg42, -OC(O)Rg41, -OC(O)ORg41, -OC(O)SRg41, -OC(O)NRg41Rg42, -OC(NRh)NRg41Rg42, -SC(O)Rg41, -SC(O)ORg41, -SC(O)NRg41Rg42, -SC(NRh)NRg41Rg42, - N(Rh)C(O)Rg41, -N[C(O)Rg41]2, -N(ORh)C(O)Rg41, -N(Rh)C(NRh')Rg41, -N(Rh)N(Rh')C(O)Rg41, -N[C(O)R43]NRg41Rg42, -N(Rh)C(S)Rg41, -N(Rh)S(O)Rg41, -N(Rh)S(O)ORg41, -N(Rh)S(O)2Rg41, -N[S(O)2Rg41][S(O)2Rg2], -N(Rh)S(O)2ORg41, - N(Rh)S(O)2NRg41Rg42, -N(Rh)[S(O)2]2Rg41, -N(Rh)C(O)ORg41, -N(Rh)C(O)SRg41, -N(Rh)C(O)NRg41Rg42, -N(Rh)C(O)NRh'NRg41 Rg42, -N(Rh)N(Rh')C(O)NRg41Rg42, -N(Rh)C(S)NRg41Rg42, -[N(Rh)C(O)][N(Rh')C(O)]Rg41, -N(Rh)[C(O)]2Rg41, -N{[C(O)]2Rg41}{[C(O)]2Rg42}, -N(Rh)[C(O)]2ORg41, -N(Rh)[C(O)]2NRg41Rg42, -N{[C(O)]2ORg41}{[C(O)]2ORg41), -N{[C(O)]2NRg41Rg42}{[C(O)]2NRg41Rg42}, -[N(Rh)C(O)][N(Rh')C(O)}ORg41, N(Rh)C(NRh')ORg41, -N(Rh)C(NOH)Rg41, -N(Rh)C(NRh')SRg41, -N(Rh)C(NRh')NRg41Rg42; y N=C(Rh)NRg41Rg42; y cada Rg4, Rg41, Rg42 y Rg43, independientemente entre sí, representa hidrogeno o un grupo seleccionado entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, donde Rg41 y/o Rg42 y/o Rg43 tomados juntos pueden formar un resto heterocicloalquilo de 3-8 miembros a través de un átomo compartido de C, N, O o S, donde cada Rg41, Rg42 y Rg43 está opcionalmente sustituido independientemente con uno o más iguales o diferentes Rhö; y cada Rh, Rh' y Rhö se selecciona independientemente entre otro de hidrogeno, alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, donde Rh y Rh' tomados juntos pueden formar un resto heterocicloalquilo de 3-8 miembros a través de un átomo compartido de C, N, O o S, y cada R5 representa un grupo seleccionado entre Ra5 y/o Rb5, cada Ra5, independientemente entre sí, representa hidrogeno o un grupo seleccionado entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, donde Ra5 está opcionalmente sustituido con uno o más Rb5 y/o Rc51 iguales o diferentes; y cada Rb5 representa un grupo adecuado y se selecciona independientemente entre otro de =O, -ORc5, haloalquiloxi C1-3, -OCF3, -OCHF2, =S, -SRc5, =NRc5, =NORc5, =NNRc5Rc55, =NN(Rg5)C(O)NRc5Rc55, -NRC5Rc55, -ONRc5Rc55, -N(ORc5)Rc55, -N(Rg5)NRc5Rc55, halogeno, -CF3, -CHF2, -CH2F, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)Rc5, -S(O)ORc5, -S(O)2Rc5, -S(O)2ORc5, -S(O)NRc5Rc55, - S(O)2NRcRc55, -OS(O)Rc5, -OS(O)2Rc5, -OS(O)2ORc5, -OS(O)NRc5Rc55, -OS(O)2NRc5Rc55, -C(O)Rc5, -C(O)ORc5, -C(O)SRc5, -C(O)NRc5Rc55, -C(O)N(Rg5)NRc5Rc55, -C(O)N(Rg5)ORc5, -C(NRg5)NRc5Rc55, -C(NOH)Rc5, -C(NOH)NRc5Rc55, -OC(O)Rc5, -OC(O)ORc5, -OC(O)SRc5, -OC(O)NRc5Rc55, -OC(NRg5)NRc5Rc55, -SC(O)Rc5, -SC(O)ORc5, -SC(O)NRc5Rc55, -SC(NRg5)NRc5Rc55, -N(Rg5)C(O)Rc5, -N[C(O)Rc5]2, -N(ORg5)C(O)Rc5, -N(Rg5)C(NRg5)Rc5, -N(Rg5)N(Rg55)C(O)Rc5, -N[C(O)Rc5]NRc55Rc555, -N(Rg5)C(S)Rc5, -N(Rg5)S(O)Rc5, -N(Rg5)S(O)ORc5, -N(Rg5)S(O)2Rc5, -N[S(O)2Rc5]2, -N(Rg5)S(O)2ORc5, -N(Rg5)S(O)2NRc5Rc55, -N(Rg5)[S(O)2]2Rc5, -N(Rg5)C(O)ORc5, -N(Rg5)C(O)SRc5, -N(Rg5)C(O)NRc5Rc55, -N(Rg5)C(O)NRg55NRc5Rc55, -N(Rg5)N(Rg55)C(O)NRc5Rc55, -N(Rg5)C(S)NRc5Rc55, -[N(Rg5)C(O)]2Rc5, -N(Rg5)[C(O)]2Rc5, -N{[C(O)]2Rc5}2, -N(Rg5)[C(O)]2ORc5,-N(Rg5)[C(O)]2NRc5Rc55, -N{[C(O)]2ORc5}2, -N{[C(O)]2ORc5}2, -N{[C(O)]2NRc5Rc55}2, -[N(Rg5)C(O)]2ORc5, -N(Rg5)C(NRg55)ORc5, -N(Rg5)C(NOH)Rc5, -N(Rg5)C(NRg55)SRc5, -N(Rg5)C(NRg55)NRc5Rc55 y -N=C(Rg5)NRc5Rc55 donde Rc5 y/o Rc55 y/o Rc555 tomados juntos pueden formar un resto heterocicloalquilo de 3-8 miembros a través de un átomo compartido de C, N, O o S; y cada Rc51, Rc5, Rc55 y Rc555, independientemente entre sí, representa hidrogeno o un grupo seleccionado entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, donde cada Rc51, Rc5, Rc55 y/o Rc555 está opcionalmente sustituido independientemente con uno o más Rd5 y/o Re51 iguales o diferentes; y cada Rd5 representa un grupo adecuado y se selecciona independientemente entre otro de =O, -ORe5, haloalquiloxi C1-3, -OCF3, -OCHF2, =S, -SRe5, =NRe5, =NORe5, =NNRe5Re55, =NN(Rg5)C(O)NRe5Re55, -NRe5Re55, -ONRe5Re55, -N(Rg5)NRe5Re55, halogeno, -CF3, -CHF2, -CH2F, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)Re5, -S(O)2Re5, -S(O)2ORe5, -S(O)NRe5Re55, -S(O)2NRe5Re55, -OS(O)Re5, -OS(O)2Re5, -OS(O)2ORe5, -OS(O)NRe5Re55, -OS(O)2NRe5Re55, -C(O)Re5, -C(O)ORe5, -C(O)SRe5, -C(O)NRe5Re55, -C(O)N(Rg5)NRe5Re55, -C(O)N(Rg5)ORe5, -C(NRg5)NRe5Re55, -C(NOH)Re5, -C(NOH)NRe5Re55, -OC(O)Re5, -OC(O)ORe5, -OC(O)Sre5, -OC(O)NRe5Re55, -OC(NRg5)NRe5Re55, -SC(O)Re5, -SC(O)ORe5, -SC(O)NRe5Re55, -SC(NRg5)NRe5Re55, -N(Rg5)C(O)Re5, -N[C(O)Re5]2, -N(ORg5)C(O)Re5, -N(Rg5)C(NRg55)Re5, -N(Rg5)N(Rg55)C(O)Re5, -N[C(O)Re5]NRe55Re555, -N(Rg5)C(S)Re5, -N(Rg5)S(O)Re5, -N(Rg5)S(O)ORe5, -N(Rg5)S(O)2Re5, -N[S(O)2Re5]2, -N(Rg5)S(O)2ORe5, -N(Rg5)S(O)2NRe5Re55, -N(Rg5)[S(O)2]2Re5, -N(Rg5)C(O)ORe5, -N(Rg5)C(O)SRe5, -N(Rg5)C(O)NRe5Re55, -N(Rg5)C(O)NRg55NRe5Re55, -N(Rg5)N(Rg55)C(O)NRe5Re55, -N(Rg5)C(S)NRe5Re55, -[N(Rg5)C(O)]2Re5, -N(Rg5)[C(O)]2Re5, -N{[C(O)]2Re5}2, -N(Rg5)[C(O)]2ORe5,-N(Rg5)[C(O)]2NRe5Re55, -N{[C(O)]2ORe5}2, -N{[C(O)]2NRe5Re55}2, -[N(Rg5)C(O)]2Ore5, -N(Rg5)C(NRg55)ORe5, -N(Rg5)C(NOH)Re5, -N(Rg5)C(NRg55)SRe5, -N(Rg5)C(NRg55)NRe5Re55 y -N=C(Rg5)NRe5Re55, donde Re5 y/o Re55 y/o Re555 tomados juntos pueden formar un resto heterocicloalquilo de 3-8 miembros a través de un átomo compartido de C, N, O o S; y cada Re51, Re5,
ARP110100240A 2010-01-26 2011-01-25 5- alquinil -pirimidinas AR080019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10151722 2010-01-26

Publications (1)

Publication Number Publication Date
AR080019A1 true AR080019A1 (es) 2012-03-07

Family

ID=42140100

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100240A AR080019A1 (es) 2010-01-26 2011-01-25 5- alquinil -pirimidinas

Country Status (23)

Country Link
US (1) US8618111B2 (es)
EP (1) EP2528910B1 (es)
JP (1) JP5670479B2 (es)
KR (1) KR20130030742A (es)
CN (1) CN102781931A (es)
AP (1) AP2012006361A0 (es)
AR (1) AR080019A1 (es)
AU (1) AU2011209343A1 (es)
BR (1) BR112012018454A2 (es)
CA (1) CA2787396A1 (es)
CL (1) CL2012001926A1 (es)
CO (1) CO6592046A2 (es)
EA (1) EA201201049A1 (es)
EC (1) ECSP12012110A (es)
IN (1) IN2012DN06600A (es)
MA (1) MA33938B1 (es)
MX (1) MX2012008359A (es)
PE (1) PE20121527A1 (es)
SG (1) SG182676A1 (es)
TN (1) TN2012000370A1 (es)
TW (1) TW201139412A (es)
UY (1) UY33198A (es)
WO (1) WO2011092197A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33199A (es) * 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
US8466162B2 (en) * 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
EP0674627A1 (en) 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5622954A (en) 1994-05-11 1997-04-22 Fmc Corporation 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
JP4960085B2 (ja) * 2003-03-19 2012-06-27 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
US20060205740A1 (en) * 2003-08-14 2006-09-14 Reno Michael J Chemical compounds
WO2005060969A1 (en) 2003-12-24 2005-07-07 Astrazeneca Ab Pyrimidines with tie2 (tek) activity
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
JP2008528663A (ja) 2005-02-01 2008-07-31 アストラゼネカ アクチボラグ Ｔｉｅｓ（ＴＥＫ）阻害活性を有するピリミジン化合物
EP1846399A1 (en) 2005-02-01 2007-10-24 AstraZeneca AB Pyrimidine compounds having tie2 (tek) inhibitory activity
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2006106721A1 (ja) * 2005-03-30 2006-10-12 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するピリミジン誘導体
WO2006103449A2 (en) 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
KR20080083188A (ko) * 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
JP2010501537A (ja) 2006-08-24 2010-01-21 アストラゼネカ アクチボラグ 増殖性障害の治療に有用なモルホリノピリミジン誘導体
WO2008080965A2 (en) 2006-12-29 2008-07-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5,6-substituted pyrimidines
EP2022785A1 (en) 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
TW201010984A (en) 2008-07-29 2010-03-16 Boehringer Ingelheim Int 5-alkynyl-pyrimidines
JP2010018601A (ja) * 2009-02-16 2010-01-28 Tetsuya Nishio 複素環化合物、その製造法および用途
UY33199A (es) * 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.

Also Published As

Publication number Publication date
TW201139412A (en) 2011-11-16
CO6592046A2 (es) 2013-01-02
SG182676A1 (en) 2012-08-30
EP2528910A1 (en) 2012-12-05
JP5670479B2 (ja) 2015-02-18
CA2787396A1 (en) 2011-08-04
PE20121527A1 (es) 2012-11-21
EA201201049A1 (ru) 2013-02-28
AP2012006361A0 (en) 2012-08-31
WO2011092197A1 (en) 2011-08-04
BR112012018454A2 (pt) 2016-04-19
ECSP12012110A (es) 2012-09-28
UY33198A (es) 2011-08-31
TN2012000370A1 (en) 2014-01-30
EP2528910B1 (en) 2015-03-18
AU2011209343A1 (en) 2012-08-02
US8618111B2 (en) 2013-12-31
MA33938B1 (fr) 2013-01-02
KR20130030742A (ko) 2013-03-27
CN102781931A (zh) 2012-11-14
CL2012001926A1 (es) 2012-11-30
US20120028958A1 (en) 2012-02-02
MX2012008359A (es) 2012-08-08
IN2012DN06600A (es) 2015-10-23
JP2013518078A (ja) 2013-05-20

Similar Documents

Publication Publication Date Title
AR080020A1 (es) 5-alquinil-pirimidinas
AR078513A1 (es) Pirimidinas y composiciones farmaceuticas que las comprenden
AR072845A1 (es) 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas.
AR057423A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamento
AR074127A1 (es) 2,4 diaminopirimidinas y uso para la preparacion de un medicamento para el tratamiento de cancer, infecciones y enfermedades inflamatorias y autoinmunes
AR076134A1 (es) Derivados de 2,4 diaminopirimidinas
AR074210A1 (es) Derivados de pirimidina como inhibidores de ptk2-quinasa
AR076620A1 (es) 2,4 DIAMINOPIRIMIDINAS, COMPOSICIONES FARMACEUTICAS, PROCESOS DE PREPARACIoN Y SU USO COMO MEDICAMENTO.
AR074209A1 (es) Derivados de pirimidina utiles para el tratamiento del cancer
AR051743A1 (es) Tiazolil - dihidro- indazoles
AR060890A1 (es) Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
AR054837A1 (es) Compuestos inhibidores del virus de la hepatitis c
ES2722048T3 (es) Compuestos de triazolopirimidina y usos de los mismos
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
AR086829A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR082850A1 (es) Aminopirazoloquinazolinas
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR072538A1 (es) Derivados de indolinonas, composiciones farmacéuticas y usos
PE20160932A1 (es) Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
AR087148A1 (es) Imidazopiridazinas
AR066963A1 (es) Derivados de indolinona, preparaciones farmaceuticas que los contienen y usos de los mismos para el tratamiento y/o prevencion de cancer y enfermedades inflamatorias y autoinmunes.
AR080019A1 (es) 5- alquinil -pirimidinas
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
AR070877A1 (es) Tiazolil-dihidro-indazoles, una preparacion farmaceutica en base al compuesto y uso del compuesto para preparar un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure